DIA Biosimilars 2013

Drug Sponsors

Icon reports Q3 revenue of $286M

Monday, November 5, 2012 09:24 AM

Icon, a global provider of outsourced development services, reported its financial results for the third quarter ended September 30, 2012. Net revenues for the quarter grew 19% to $286 million compared to $241 million in the same quarter last year.

More... »

Cenduit: Now with Patient Reminders

Bayer HealthCare strengthens position in Russia

Friday, November 2, 2012 02:21 PM

Bayer HealthCare and Russian drug manufacturer Medsintez have entered into a strategic partnership to jointly manufacture and commercialize diagnostic imaging products as well as pharmaceuticals to treat infections and neural disorders.

More... »

CRF Health – eCOA Forum

Lilly to expand Indianapolis insulin manufacturing operations

Friday, November 2, 2012 10:38 AM

Global pharmaceutical company Eli Lilly announced a $140 million expansion to the company's Indianapolis insulin manufacturing operations. The 80,000-square-foot expansion, which will enable the manufacturing of insulin cartridges to meet the growing diabetes demand in the U.S., represents one of the most significant investments in Lilly's U.S.-based manufacturing operations in the past decade.

More... »

Thesan Pharmaceuticals closes $16M Series A funding

Wednesday, October 31, 2012 02:04 PM

Thesan Pharmaceuticals, a newly-formed biotech focused on dermatological conditions, has closed a $16M Series A financing, co-led by Novo Ventures and Novartis Venture Funds. 

More... »

Novartis to build $500M biotech facility in Singapore

Wednesday, October 31, 2012 01:38 PM

Novartis has decided to construct a new state-of-the-art biotechnology production site in Singapore with an investment valued at over $500 million.

More... »

Theratechnologies revises business plan, cuts 15 employees

Wednesday, October 31, 2012 10:39 AM

Theratechnologies, a Canadian specialty pharmaceutical company focused on therapeutic peptide products, has revised its business plan which will focus on revenue growth from tesamorelin in the short term and expenditure control.

More... »

Connecticut Innovations invests $1.5M in New Haven Pharmaceuticals

Wednesday, October 31, 2012 10:11 AM
Summary not available

More... »

Apredica, Pfizer ink collaborative research agreement

Wednesday, October 31, 2012 09:43 AM

Apredica, a subsidiary of Cyprotex, a preclinical ADME-Tox services company, has signed a collaborative research agreement with Pfizer, a global research-based pharmaceutical company.

More... »

Bayer to acquire Schiff Nutrition International for $ 1.2B

Wednesday, October 31, 2012 09:15 AM

Bayer HealthCare has signed a merger agreement to acquire Schiff Nutrition International, a company offering vitamins and nutritional supplements in the U.S. and other countries, for $1.2 billion, representing a value of $34 per share in cash.

More... »

Aveo refocuses on tivozanib, cuts 17% of workforce

Tuesday, October 30, 2012 01:43 PM

Aveo Oncology, a cancer therapeutics company based in Cambridge, Mass., has announced a strategic restructuring designed to optimize resources and reduce expenses to ensure Aveo is well positioned for a successful launch of tivozanib in renal cell carcinoma (RCC) and continued development in other cancer types, while maintaining a focused research engine.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs